AARD · Aardvark Therapeutics Inc
United States · RS rating 6 · As of 2026-10-14
| Price | 3.88 USD |
|---|---|
| 1-day change | -4.0% |
| RS rating (overall / 1M / 3M / 12M) | 6 / 10 / 8 / 8 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 17 / 18 / 13 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -8.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +75.5% |
| Market cap (USD) | $117.2M |